United States: FDA: Streamlining Regulations For Clinical Research

Title III of the 21st Century Cures Act includes portions of the FDA Device Accountability Act of 2015, Promoting Biomedical Research and Public Health for Patients Act, and FDA and NIH Workforce Authorities Modernization Act. These bills were introduced, but not advanced, by the US Senate.

The prevalence of precision medicine, innovative cures and individualized patient treatments has caused FDA and other regulators to rethink traditional approaches to clinical research. Recent FDA initiatives to encourage adaptive clinical trial designs for novel therapies may signal a move toward greater flexibility regarding the types of clinical evidence and data that is adequate to support a product approval. The clinical trial portions of this legislation focus on streamlining clinical research by harmonizing human subject research protections and informed consent requirements across agencies, so that FDA's human subject regulations are more in line with the human subject regulations of the US Department of Health and Human Services (HHS), which are known as the Common Rule. The bill also offers researchers the flexibility to use non-local institutional review boards (IRB) for investigational and humanitarian use devices and novel clinical trial designs and data in the drug and biological products approval and licensure processes.

3021. Novel Clinical Trial Designs

The Cures legislation requires FDA to hold a public meeting and issue guidance to assist sponsors in incorporating complex adaptive and other novel trial designs into proposed clinical protocols and applications for new drugs and biological products. Among other items, the new guidance must address the use of such designs to demonstrate the safety and effectiveness of new drugs under the substantial evidence standard (evidence of adequate and well-controlled investigations) for FDA approval of new drugs. The guidance must also address how to submit information from modeling and simulations. This future guidance has the potential to significantly broaden the methodologies of analysis and data that may be used to support the approval and licensure of new products.

In the provision, Congress does not explicitly state whether it intends for the agency to finalize the policies set forth in the 2010 adaptive design draft guidance as-is, or if it expects the agency to make meaningful revisions to that document. However, this section of the legislation suggests that Congress expects FDA to be more flexible in evaluating the evidence of safety and effectiveness to support new drug and biological product applications. Companies with applications pending before the agency (or preparing to submit such applications) should consider leveraging the legislative language to support arguments that safety and effectiveness can be evaluated with more flexible and/or modern trial designs than FDA has traditionally required.

Additionally, sponsors and other stakeholders should consider attending the public meeting and submitting written or oral comments to inform FDA's development of the guidance.

3023. Protection of Human Research Subjects

Effecting a change long sought by researchers, the legislation requires the HHS secretary to harmonize differences between HHS and FDA regulations for the protection of human subject (generally) and vulnerable populations (specifically). The harmonization effort may modernize the regulations to facilitate multi-site and cooperative research projects, avoid regulatory duplication and delays, protect vulnerable populations, and encourage community engagement. Additionally, the legislation encourages sponsors of research that is subject to both HHS and FDA human subject regulations to use a joint or centralized IRB review process. This provision may benefit multi-site trials by consolidating the IRB process.

This section streamlines the process by which human subject research may be reviewed and conducted. This harmonization effort will likely impact the current efforts to amend the Common Rule, which were outlined in a 2015 notice of proposed rulemaking. However, the proposed rulemaking may serve as a guidepost for the effort. For example, the proposed rulemaking would require that cooperative research or multisite studies rely on a single IRB, with limited exceptions, which is consistent with the flexibility proposed under certain circumstances in Section 3056 of the Cures legislation (described below). The extent to which HHS will change any individual provision is unclear at this time, but potential targets are revision of the types of studies that require IRB review and oversight, allowable IRB exemptions, inconsistent definitions (e.g., research, human subject), and various aspects of the informed consent process. For example, harmonization efforts may make it easier for sponsors to obtain and use retrospective analyses of de-identified data, which have historically been exempt from the informed consent requirement under the Common Rule but not expressly exempt under FDA regulations. The possibility of establishing an analogous exemption under FDA requirements may significantly increase the extent to which sponsors rely on such analyses to support product development and other activities. Entities that perform human subject research should monitor HHS's efforts to consult with stakeholders and the Federal Register for additional opportunities to comment on the harmonization process, rulemakings and guidance, as this section arguably provides an opportunity to broaden the exceptions to when informed consent is required for FDA-regulated clinical investigations.

3024. Informed Consent Waiver or Alteration for Clinical Investigators

The legislation allows FDA's informed consent requirements to be waived or altered for trials of investigational drugs or devices if the proposed clinical tests pose no more than minimal risk to the human subjects and include appropriate safeguards to protect the rights, safety and welfare of the subjects. The legislation does not define the phrase "no more than minimal risk" and does not cross-reference any existing HHS or FDA regulations or guidance to provide insight as to how such language should be interpreted by the FDA. Although the phrase is not defined in the US Code, FDA has defined in 21 C.F.R. § 50.52 what constitutes a clinical investigation involving greater than minimal risk to children. Under that regulation, an IRB must find that (1) the risk is justified by the anticipated benefit to the subjects; (2) the relation of the anticipated benefit to the risk is at least as favorable to the subjects as that presented by available alternative approaches; and (3) adequate provisions are made for soliciting the assent of the children and permission of their parents or guardians as set forth in a separate FDA rule. The FDA's interpretation of the phrase and the language on the "appropriate safeguards" required to protect human subjects will likely require a separate rulemaking or guidance, as the broad statutory language "no more than minimal risk" could be construed in many different ways.

To the extent that FDA's interpretation of "no more than minimal risk" tracks existing HHS regulations on the protection of human research subjects, this section could potentially harmonize FDA's informed consent requirements with existing HHS and National Institutes of Health (NIH) requirements under the Common Rule. For example, in 45 C.F.R. § 46.102, HHS defines "minimal risk" as "the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests." Additional HHS regulations discuss "minimal risk" in the context of research involving not greater than minimal risk to children, research involving greater than minimal risk that presents the prospect of direct benefit to the individual subjects, and research involving greater than minimal risk and no prospect of direct benefit, but that is likely to yield generalizable knowledge about the subject's disorder or condition. FDA may examine the protections in these HHS regulations on "minimal risk" and "greater than minimal risk" to establish appropriate safeguards.

Depending on FDA's interpretation of the phrase "no more than minimal risk," stakeholders that perform, participate in, and/or evaluate investigational drug and device human subject research may have greater freedom to pursue trial designs that were previously impractical under FDA regulations. This legislative change could provide new opportunities for sponsors to use "big data," in particular in retrospective analyses of de-identified data, in submissions to the agency, as such analyses arguably pose no more than a minimal risk to patients.

3056. Institutional Review Board Flexibility

The Cures legislation strikes references to "local" IRBs in the investigational and humanitarian device exemptions, which exempt such devices from requirements including labeling, registration, premarket approval, recordkeeping and reporting. Sponsors, investigators and others involved in a device trial or other device use (e.g., diagnosis or treatment) within the scope of the exemptions will now be allowed to engage a centralized or other non-local IRB for review and approval. This section is consistent with the trend toward centralization of IRB operations and avoidance of duplication of review, especially as associated with multi-site trials.

Sponsors should re-examine their plans for trials and centralize the IRB process insofar as use of a local IRB was intended solely to address FDA requirements. This legislative change may ease the process of beginning a clinical trial and addressing ongoing oversight of a trial. Stakeholders— including investigators, health care providers and medical centers—that administer trials or perform patient services with investigational or humanitarian devices may need to modify existing practices, policies and procedures to allow for review by non-local IRBs.

FDA: Streamlining Regulations For Clinical Research

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions